Frank Vinluan
Frank is a business journalist with more than a decade of experience covering various aspects of technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. Frank has a bachelor’s degree in history from Carleton College and a master’s degree in public affairs reporting from the University of Illinois Springfield.
Recent posts
Urovant Sciences says its experimental drug for overactive bladder could offer advantages compared to an FDA-approved treatment marketed by Astellas Pharma. But late-stage clinical results released Tuesday raise questions whether Urovant... Read more »
An experimental drug developed by Dermira to treat atopic dermatitis has hit the main goal of its mid-stage study, helping to build a case that the injectable treatment could measure up... Read more »
While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was... Read more »
X4 Pharmaceuticals is the latest biotech to join the public markets, but it didn’t follow the IPO path to get there.
Cambridge, MA-based X4 said Wednesday that it completed its “... Read more »
An experimental multiple sclerosis treatment identified as a key asset in Bristol-Myers Squibb’s proposed acquisition of Celgene has been filed for regulatory approval in Europe.
Celgene (NASDAQ: CELG) submitted its... Read more »
It’s been more than three years since the FDA approved salmon from AquaBounty Technologies, but debates about labels and other requirements have kept the genetically engineered fish from reaching dining plates.... Read more »
An experimental Vertex Pharmaceuticals cystic fibrosis treatment that combines three of the company’s drugs has hit the main goals of two late-stage studies.
It’s the second cystic fibrosis (CF) three-drug cocktail... Read more »
Eli Lilly is planning to offer a generic version of its blockbuster insulin product that will cost patients approximately half as much.
The Indianapolis-based pharmaceutical giant said Monday that the authorized... Read more »
Precision BioSciences has filed for an initial public offering to continue its development of gene-edited cell therapies, including a cancer treatment that is set to start tests in humans in the... Read more »
Swallowing a pill is a convenience that’s not available for all drugs. The cells and proteins in biological therapies can’t survive digestive enzymes, whose role is to break things down. That’s... Read more »
Microbiome drugs developer Kaleido Biosciences is joining the ranks of publicly traded biotechs, but it had to sell more shares and cut their price.
The Lexington, MA, company priced its downsized... Read more »
[Updated 2/28/19, 11:58 a.m. See below.] Bristol-Myers Squibb’s agreement to acquire Celgene for $74 billion is opposed by the New York pharmaceutical company’s largest institutional investor.
Wellington Management Group said... Read more »
[Updated 6:16 p.m. See below.] Plant-based foods and beverages are getting more grocery store shelf space as consumers increasingly shop for meat and milk alternatives. But these products typically... Read more »
A Karyopharm Therapeutics multiple myeloma drug candidate faces longer odds for speedy FDA approval after the agency’s staff raised questions about the therapy’s efficacy and safety.
Staff concerns about Karyopharm drug... Read more »
Voyager Therapeutics and AbbVie, already partners developing gene therapies for Alzheimer’s disease, are now expanding their alliance to include Parkinson’s.
AbbVie (NYSE: ABBV) is paying Cambridge, MA-based Voyager (NASDAQ: VYGR... Read more »
The growing epidemic of the fatty liver disease known as NASH, which has no FDA-approved treatment, has led to a frenzied race among drug companies. This week, one company, Intercept Pharmaceuticals,... Read more »
Four months after Immune Design halted a late-stage study for its lead cancer vaccine and saw its stock price cut nearly in half, the immunotherapy company is now in line to... Read more »
Activist hedge fund Starboard Value has boosted its stake in Bristol-Myers Squibb and nominated five candidates to serve on the pharmaceutical giant’s board of directors.
Bristol-Myers (NYSE: BMY) disclosed Starboard’s... Read more »
Stealth BioTherapeutics has popped up on the radar with a $78 million IPO to fund clinical trials for drugs treating rare mitochondrial disorders.
Shares of Stealth Bio (NASDAQ: MITO) made... Read more »
Bayer has just reclaimed some rights to two drugs from Loxo Oncology, which means it’s going to take more work for Loxo’s buyer, Eli Lilly, to justify the $8 billion it... Read more »
